Osteoarthritis in the UK Armed Forces: a review of its impact, treatment and future research

Oliver O'Sullivan (1,2 F P Behan (1,3 R J Coppack, 1,4 J Stocks (1,2 S Kluzek, 2,4 A M Valdes, 2,5 A N Bennett^{1,6}

ABSTRACT

¹Academic Department of Military Rehabilitation, DMRC Stanford Hall, Loughborough, LE12 50W. UK ²Academic Unit of Injury, Recovery and Inflammation Sciences, University of Nottingham, Nottingham, UK ³Department of Bioengineering, Imperial College London, London, UK ⁴Centre for Sport, Exercise and Osteoarthritis Research, Versus Arthritis, Nottingham, UK ^bDepartment of Twin Research and Genetic Epidemiology, King's College London, London, UK ⁶National Heart and Lung

Institute, Faculty of Medicine, Imperial College London, London, UK

Correspondence to

Maj Oliver O'Sullivan, Academic Department of Military Rehabilitation, DMRC Stanford Hall, Loughborough, UK; oliver_ osullivan@hotmail.com

Received 2 March 2023 Accepted 31 May 2023

Check for updates

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: O'Sullivan O, Behan FP, Coppack RJ, et al. BMJ Mil Health Epub ahead of print: [please include Day Month Year]. doi:10.1136/ military-2023-002390 Within the UK Armed Forces, musculoskeletal injuries account for over half of all medical downgrades and discharges. Data from other Armed Forces show that osteoarthritis (OA), more common in military personnel, is likely to contribute to this, both in its primary form and following injury (post-traumatic OA, PTOA), which typically presents in the third or fourth decade. OA is not a progressive 'wear and tear' disease, as previously thought, but a heterogenous condition with multiple aetiologies and modulators, including joint damage, abnormal morphology, altered biomechanics, genetics, low-grade inflammation and dysregulated metabolism. Currently, clinical diagnosis, based on symptomatic or radiological criteria, is followed by supportive measures, including education, exercise, analgesia, potentially surgical intervention, with a particular focus on exercise rehabilitation within the UK military. Developments in OA have led to a new paradium of organ failure, with an emphasis on early diagnosis and risk stratification, prevention strategies (primary, secondary and tertiary) and improved aetiological classification using genotypes and phenotypes to guide management, with the introduction of biological markers (biomarkers) potentially having a role in all these areas. In the UK Armed Forces, there are multiple research studies focused on OA risk factors, epidemiology, biomarkers and effectiveness of different interventions. This review aims to highlight OA, especially PTOA, as an important diagnosis to consider in serving personnel, outline current and future management options, and detail current research trends within the Defence Medical Services.

BACKGROUND

Musculoskeletal injuries (MSKI) are a significant burden for the UK Armed Forces, accounting for 54% of medical discharges between 2015 and 2020 and 56% of medical downgrades between 2010 and 2020.¹ As a result, the Defence Medical Services (DMS) prioritises MSKI research to understand the epidemiology, causes and mechanisms in order to optimise existing and develop new prevention, mitigation and management strategies.² Typically, these injuries occur during the initial stages of training, after strenuous activity or as a result of trauma, most commonly affecting the lower limbs and spine.

A key and underacknowledged pathology in the UK military population is osteoarthritis (OA), accounting for 10% of all US military MSKI-related discharges.^{3 4} OA is a synovial joint organ disease characterised by progressive deterioration and

WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Musculoskeletal injuries are the leading cause of medical downgrade and medical discharges within the UK Armed Forces, with osteoarthritis (OA) contributing significantly to this burden.
- ⇒ OA is a heterogenous synovial joint disease, with multiple aetiologies and contributing factors, leading to a clinical syndrome of pain, stiffness, increased physical inactivity and reduced function; more common in military personnel, in both the primary, idiopathic form, and the secondary, post-traumatic form (posttraumatic OA, PTOA).

WHAT THIS STUDY ADDS

- ⇒ Currently under-recognised within the UK military, this review of OA aims to articulate the importance and impact of this common and disabling condition by discussing underlying pathophysiological mechanisms, the contribution of individual and risk factors and current management options.
- ⇒ This study introduces new concepts into the military, such as a model of 'organ failure' for OA, the role of differing prevention strategies to mitigate or slow disease progression and use of phenotyping and biomarkers to guide risk stratification and interventions.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ This study aims to highlight OA and PTOA as diagnoses to consider, especially in those with prolonged joint pain following traumatic injury, by demonstrating evidence-based current and future clinical management to guide best practice of those at risk or diagnosed with OA, and highlighting the future research trends within the Defence Medical Services and how these will offer the potential to improve the management of OA for service personnel.

loss of articular cartilage, resulting in structural and functional changes in the joint's synovium, meniscus, ligaments and bone.⁵ The National Institute for Health and Care Excellence (NICE) recommends pragmatic clinical diagnosis of OA in those ≥ 45 years old, following 3 months of joint pain, made worse by activity.⁶ This condition affects approximately 10 million people in the UK and is one of the leading causes of disability on a global scale due to increased physical inactivity




Figure 1 Overview of individual and risk factors contributing to the spectrum of osteoarthritis (OA) and potential role of biological markers throughout the disease continuum, in support of primary, secondary and tertiary prevention strategies of the medical chain. ADLs, activities of daily living; BMI, body mass index; QoL, quality of life.

and associated development and progression of cardiometabolic disease and other comorbidities.⁶⁷

Previously thought to be a progressive 'wear and tear' degenerative disease, it is now understood to be a heterogenous process with distinct underlying pathophysiological pathway and interaction between modifiable and non-modifiable risk factors and individual features (figure 1). Significantly, OA is more prevalent among military personnel due to their physically demanding jobs and increased risk of specific exposure to trauma and vibration.⁸ ⁹ In addition, a distinct subtype, posttraumatic OA (PTOA), is common in military populations due to increased exposure to major or repeated microtrauma.^{4 10} Due to its accelerated pathophysiological process and typical manifestation in the third or fourth decade, PTOA can have a long-lasting impact on individuals and their occupations.¹¹ A recent study showed that, following a knee injury, one in six US military officers developed OA by age 30.¹⁰

The purpose of this paper is to highlight OA, specifically PTOA, as an important diagnosis to consider in the military population to improve awareness and appropriate diagnosis, suggest current and future management options and introduce current research trends.

POST-TRAUMATIC OSTEOARTHRITIS

PTOA develops following traumatic injury, with certain injuries, such as cruciate ligament rupture, meniscal tear, and patella, ankle or shoulder instability strongly linked to subsequent development.¹² It has been estimated that 13% of knee PTOA can be directly attributed to previous trauma.¹² The initial traumatic episode results in localised disruption of articular cartilage, cartilage fissures and chondrocyte death, accompanied by a post-traumatic inflammatory response and synovitis, as well as

concurrent damage affecting biomechanical function of the joint, including fractures.^{4 13 14} It is not solely irreversible mechanical damage that leads to PTOA, but a combination of enduring chronic inflammation, hypoxia, biomechanical changes, genetic factors and individual predispositions, with symptoms appearing within 2–5 years of initial injury.^{9 12 15}

PATHOPHYSIOLOGICAL MECHANISMS

After an injury, the joint undergoes activation of multiple signalling pathways, resulting in cartilage matrix degradation and synovial inflammation leading to a process of repair, remodelling and adaptation.¹⁴ However, aberrant mechanistic pathways can contribute to a lack of repair and remodelling, inadequate adaptation and the subsequent development of OA, with altered joint biomechanics, metabolism and low-grade inflammation all playing crucial roles.⁷ ¹² OA is a heterogenous condition, and the balance of each contributing factor is likely to be different. Differences can be described as the endotype, related to the contributing mechanism, or the phenotype, relating to the condition's presentation (see table 1). Studying differing phenotypes allows understanding of their underlying inflammatory pathway, metabolic and biomechanical changes, setting the conditions for optimised and personalised interventions.

Inflammation, both local and systemic, plays a key role in the initial pathogenesis and ongoing progression, often demonstrated by the presence of joint synovitis and effusion.^{16 17} In contrast to inflammatory arthritides, such as rheumatoid arthritis, the inflammation is 'low-grade', with standard histological staining revealing low-moderate inflammation in OA synovial tissue.¹⁷ This ongoing inflammatory response offers an insight into OA development and progression, and a potential target for pharmacological intervention.

Table 1 Classification of typing and applicability to osteoarthritis management			
Genotype	The complete genetic material of an individual, inclusive of specific variants.		
Phenotype	Observable characteristics—interaction between genotype and environment. Can include physical characteristics such as symptoms, biochemical and physiological characteristics.		
Endotype	Condition subtype distinguished by distinct causes or mechanisms, allowing identification of subgroups who require different treatments.		
Endophenotype/intermediate phenotype	Measurable characteristics related to a particular disease, influenced by genetic factors. They are more proximal to the underlying genetics of the disease than visible clinical symptoms, therefore closely tied to the underlying biological mechanisms. Studying intermediate phenotypes and underlying genetic risk factors and biological mechanisms allows identification of disease endotypes and effective targeted treatments.		

Joint surface incongruity and instability (against which the periosteal cells and synovium form osteophytes) also contributes, leading into joint biomechanical changes, influencing weight bearing, gait and overall joint function.¹⁴ This is reinforced by activation of mechanosignalling pathway and resultant mechanoinflammation.¹³ Biomechanical-based physical rehabilitation interventions can improve function and interrupt the negative feedback loop of ongoing inflammation, with research into limited surgical techniques, such as joint distraction, also showing restoration of the mechanical and biochemical joint environment.¹³

Changes in the synovial fluid composition, due to synovial injury, hypoxia and haemarthrosis, are also involved. Recent research has demonstrated that these alterations can, for instance, result in insufficient lubrication of the joint boundary, thereby diminishing joint function.¹⁹ In addition, changes in synovial fluid provide an immediate window into the local environment, and the current practice of compensated polarised light microscopy to identify crystal arthropathies such as gout (negatively birefringent) or pseudogout (positively birefringent) could be extended to investigate the predominant OA pathological process.

Further mechanisms relate to metabolic processes, including the interactions between glucose and lipid pathways.²⁰ Metabolic syndrome is felt to potentially have a bidirectional relationship with prolonged inflammation and activation of the innate immune system, further contributing to the ongoing dysregulation and pathological processes, causing accelerated OA progression and increased pain modulation.^{7 21} Animal studies suggest hypercholesterolaemia, dysregulated lipid metabolism and cholesterol accumulation are associated with the development and progression of OA, meaning that dietary interventions, weight optimisation and medication might help reduce and reverse this process.²¹

RISK AND INDIVIDUAL FACTORS

Modifiable and non-modifiable risk factors increase the likelihood of OA development and progression (figure 1). Females are both more likely to develop OA and suffer sporting injuries.⁷ Preceding joint injury, both traditional MSKI and combatassociated injuries such as amputations, contributes through altered loading,²² and by increasing physical inactivity, body mass index (BMI) and impairing physical function.^{11 15} High BMI increases OA risk by up to 30%, often preceding the onset, exhibiting bidirectional causality with both conditions influencing each other. Concurrent joint disease, as well as joint alignment, morphology and muscle strength, can lead to poor biomechanics and mechanoinflammation.¹³ Non-modifiable risk factors include sex, genetics and immunological predisposition. Individual factors, such as pain processing, sensitisation and modulation, and anxiety, depression, and other mental health conditions, can negatively affect the individual's experience of OA.⁷

MANAGEMENT OPTIONS

Joints, particularly large joints, should be treated as organs: complex structures containing a variety of tissues with a common aim: to allow load transfer and movement. Joint injuries are organ injuries causing intermittent or prolonged dysfunction, potentially leading to joint organ failure requiring external clinical intervention to maintain homeostasis. Current clinical thinking is comparable to that of cardiology a few decades ago: identification of those at risk, use of accurate measures to report function/dysfunction, and introduction of new acute management and secondary preventative interventions.

Current treatment options for OA are palliative, with the focus on living well, prolonging joint lifespan, maximising function and improving quality of life. NICE recommends the use of supportive measures, such as education, exercise and weight loss, supported by analgesia (including non-steroidal and steroidal anti-inflammatories), physiotherapy and surgery when the joint organ has failed.⁶ Exercise rehabilitation offers benefits for symptoms, BMI and modulation of inflammation and should include cardiovascular, open and closed kinetic chain, neuromuscular control, mobility and joint muscle-specific plyometrics.¹¹

Recent guidance also recommends the use of primary, secondary and tertiary preventions to improve knee health with common themes which can be mapped across to other joints (figure 1).^{7 11} The OPTIKNEE initiative aims to provide consensus on OA secondary prevention options prior to symptomatic or functional problems, with the authors stating that this should be seen as a 'call to action' for MSKI clinicians and researchers.¹¹ Their recommendations focus on a 'whole lifespan approach' to improve joint global health using a patient-centred approach (table 2)—an approach mirrored by UK Defence Rehabilitation, who are tasked to deliver occupationally focused rehabilitation and return individuals to full function and operational deployment.¹

Beyond analgesia, there are no effective pharmacological interventions for OA; however, there is a renewed focus on the development of disease-modifying antiosteoarthritis drugs.²³ These have proven difficult and costly to develop, in part due

Table 2 OPTIKNEE clinical and research recommendations to knee health promotion and post-traumatic OA prevention (adapted from Whittaker *et al*¹¹)

Clinical recommendations	Research recommendations
Prioritise single and multistructure injuries which fail to respond as expected or have subsequent injury.	Prioritise symptomatic over radiographic osteoarthritis, and understand the influence of the social determinants of health.
Create person-centred interventions to mitigate modifiable risk factors, including education, self-management and exercise. These should start early and continue for lifespan.	Studies should include a range of pathologies with risk and rehabilitation outcomes monitored for 5 years or more.
Acute injury management should centre on education, with initially supervised and progressive patient-centred rehabilitation. Programmes should include a variety of exercises and prioritise return to activity, engagement and self- management.	Monitor pain, adverse events, quality of life, cognitive-behavioural factors, function, strength, activity participation and a global assessment. Standardisation of outcome measures used should occur.
Monitor pain, adverse events, quality of life, cognitive-behavioural factors, function, strength and activity participation.	
OA, osteoarthritis.	

to study population selection, given that OA has a heterogenous population who respond differently depending on endotype and phenotype, and lack of consensus regarding outcome measures to monitor response.^{23–25}

DIRECTIONS OF FURTHER RESEARCH

The current key research priorities are to understand pathophysiological mechanisms, earlier recognition and diagnosis, and optimalisation of prevention and management strategies (particularly relevant for PTOA, as the index trauma should initiate secondary prevention interventions).^{7 10 11 25}

A particular challenge in the research and clinical fields relates to the significant discordance between imaging (radiographic or structural OA), knee pain (symptomatic OA) and a physiciandiagnosed OA; a result of the poorly understood interactions between risk and individual factors (figure 1). A recent US military study showed less than half of those with radiological OA reported symptoms.¹⁰ Another way to frame this discordance is to describe either the OA *disease* (underlying pathophysiology and cellular biology) or the OA *illness* (an individual's feeling or experience, characterised by symptoms, function and quality of life).¹¹ Regardless of terminology used, this phenomenon has implications for the design of clinical research studies, understanding pathways and markers associated with disability, dysfunction and pain, as well as future OA diagnostic criteria.

OA BIOMARKERS

An area of particular interest, cutting across all the OA research themes, is the use of biological markers, or biomarkers (products created during a pathological process), and their use to diagnose disease, stratify treatment, monitor disease progression, predict treatment response and evaluate the effectiveness of new therapies. Specific pathological changes in cartilage, bone and synovium, and concurrent inflammatory and metabolic responses, can be indirectly measured, allowing the identification of homogeneous subgroups/phenotypes based on shared clinical, epidemiological and biochemical characteristics.^{20 23} All of these measures are components of a continuum extending from genome proximity to a clinical phenotype of a painful joint limiting function.

Biomarkers can be divided into wet (serum, plasma, urine or synovial fluid) and dry (USS or MRI), or defined by their role using the BIPEDS classification (burden of disease, investigative, prognostic, efficacy of intervention, diagnostic and safety).²⁵ Biomarkers can be used to provide an early signal of joint changes, demonstrate specific mechanisms (such as inflammation, boundary lubrication and changes in glucose metabolism) and judge the impact of management (including diet, exercise or future disease modifying anti-osteoarthritis drugs (DMOADs)) (figure 1). Most current serum biomarkers demonstrate ongoing catabolism or anabolism of bone, cartilage and collagen or measure active local inflammation (table 3), and therefore can identify pathological processes before any symptomatic, structural or functional impact. This makes them ideal for use in identifying those at high risk who need prevention or active intervention, and to measure the effect of those interventions.

Imaging biomarkers, including X-ray (XR), USS and MRI, can be used to monitor joint recovery following significant trauma. XR determines the presence and severity of OA by identifying osteophytes and the degree of joint space narrowing, and is no longer used for diagnosis, but continues to be used for prognostication and research. Unlike XR, USS enables the assessment of active changes and monitoring of joint irritation, recovery and OA development by reliably monitoring synovitis and synovial thickening.²⁶ In addition, MRI allows both sequential and functional imaging to assess, in great detail, the changes related to OA development in different joint components.²⁷

GENOTYPES, PHENOTYPES AND ENDOTYPES

The use of genotyping, phenotyping and endotyping has been suggested to categorise OA subgroups and target appropriate investigations and interventions (table 2).²³ Currently, this remains crude, with categories such as primary (or idiopathic) and secondary, such as PTOA.

Understanding the underlying genotype allows specific mechanisms to be targeted. A recent study discovered that common polymorphisms in ALDH1A2, which encode the key enzyme for all-trans retinoic acid synthesis, are associated with severe OA, and that in this group, responses to injury were reversed using talarozole, a retinoic acid metabolism blocking agent.²⁸ This is a good example of the translation of a genetic mechanism and relationship with cartilage injury and inflammation into a tangible treatment model.

Identification of phenotypes and endotypes using biomarkers would also allow targeted recruitment into trials, focusing on treatment responders, specific interventions which centre on symptoms, such as pain or stiffness, or more aggressive management of those who have a quickly progressive phenotype. The identification of intermediate phenotypes that could parse the heterogeneous population of patients with PTOA into subgroups

Table 3 Validated serum osteoarthritis biomarkers and their associated pathological process			
Biological marker name	Pathological mechanisms or associations		
Type II collagen pro-peptide (CPII)	Cartilage turnover and synthesis		
Cartilage oligomeric matrix protein (COMP)	Cartilage breakdown, osteophyte development, disease progression		
C-terminal telopeptide of collagen type II (CTX-II)	Collagen type II degradation, cartilage calcification, bone resorption and osteophyte development		
Fragment of type III collagen degradation (C3M)	Radiographic changes, positive associations with weight loss and exercise		
Serum fragment of aggrecan (ARGS)	Disease severity, response to exercise		
Hyaluronic acid (HA)	Osteophyte development, synovitis		
Matrix metalloproteinase 3 (MMP-3)	Proteolytic enzyme, collagen degradation, remodelling		
Interleukin 6 (IL-6)	Proinflammatory cytokine, inflammatory mediator		
Metabolites of C-reactive protein (CRPM)	Inflammatory derivative, radiographic changes, function, positive associations with weight loss and exercise		
Leptin	Proinflammatory influence, disease severity, mediates obesity and osteoarthritis association		

with more homogeneous treatment responses could aid the s development of a 10-year risk model like current osteoporosis or management. There is also a potential role for artificial intelligence and machine learning in the prediction of phenotype response to treatment.

DEFINING RESPONSIVENESS IN OA

Due to the different OA trajectories, with individuals with varied phenotypes progressing and responding to interventions in varied ways, consensus needs to be drawn on which standardised outcome measures to use.^{11 25} These should involve both subjective patient-reported outcome measures (PROMs) to record symptoms and function, and objective markers, including functional measures such as strength or mobility assessments, and imaging, to assess structural changes. This would hope-fully mitigate the challenges associated with OA 'illness' versus 'disease'. Furthermore, the increasing use of biomarkers makes translation of the endotypes and phenotypes into therapeutic studies feasible, allowing the recruitment of homogenous study populations to improve responsivity and enable meta-analyses.²⁴

DMS CURRENT AND FUTURE RESEARCH STUDIES

OA research is a priority within the Armed Forces, both in the UK and internationally.^{4 15} Within the Academic Department of Military Rehabilitation, there are multiple studies focused on prevalence, mechanisms and biomarkers, and management.

The Armed Services Trauma and Rehabilitation Outcome (ADVANCE) study is a 20-year cohort study of 579 male combat casualties and 566 matched participants comparing medical and psychosocial outcomes of military personnel exposed and not exposed to significant combat-related trauma.²⁹ The presence of OA will be assessed using knee and hip radiographs, with the impact measured using functional tests such as the 6 minute walk test and PROMs related to pain and function. The baseline analysis results are expected in 2023 and will allow a greater understanding of the prevalence of OA in injured and non-injured individuals, thereby understanding the risk of military

service on developing OA, the risk of traumatic injury on developing PTOA, and the identification and impact of specific OA risk factors like injury type and severity. This cohort will also enable subgroup analysis of individuals who underwent traumatic lower limb amputation. This will allow the implications of combat-associated amputations and combat-related knee injuries on OA to be explored. Furthermore, this analysis will investigate those who were injured but had neither a lower limb amputation nor knee injury, to explore whether systemic combat-related trauma (eg, blast) increases OA risk without local trauma.

Using the same population, the Biomarkers and Joint Pain in Military Osteoarthritis (BioMilOA) study aims to understand the role of serum biomarkers, both presence and change of, between those with and without radiographic PTOA and investigate their predictive value for incidence, and worsening over time, of radiographic OA, joint pain and function. This study, a collaboration between ADVANCE and the University of Nottingham, will allow the role of biomarkers to be better understood in a large military population, laying the foundations for targeted surveillance and intervention, and providing a unique opportunity to compare baseline and follow-up factors in those with painful and non-painful PTOA and idiopathic OA. While the primary focus will be on those sustaining trauma, it will also provide important data on the utility of biomarkers in a general military population.

The higher rates of OA seen in active populations are believed to be linked to the increased physical activity and greater mechanical joint loading compared with sedentary occupations, but evidence of a causal link remains elusive despite the intuitive appeal of this.³⁰ There is also a lack of published data reporting the risk factors for prearthritic disorders in military personnel.³¹ The recently completed Military Hip Rehabilitation Outcome (MILO) study incorporated a population-based case–control study investigating the risk factors for non-arthritic hip pain in relation to lifelong, cumulative occupational physical workload in UK military personnel to inform the development of targeted prevention programmes.³²

Treatment modality	Treatment content	Treatment goals	Frequency per week (duration)
Group exercise	Strengthening exercises, active range of motion exercises, functional balance drills, gait drills, progressive coordination drills, non-weight-bearing aerobic/endurance exercise and minor team games.	Restore strength of deep hip stabilisers, improve core strength, increase joint range of motion, improve balance and neuromotor control, improve muscle endurance and promote group cohesion and social support.	12 (30–45 min)
Individual physiotherapy*	Manual therapy techniques, muscle activation and timing patterns, active and passive range of motion exercises, advice on home exercise, gait re-education training.	Improve quality and timing of movement, improve muscle strength, reduce pain, increase joint range of motion, induce relaxation and promote normal walking gait.	5 (30 min)
Hydrotherapy/swimming	Non-weight-bearing aerobic exercise, strengthening exercises, active range of motion exercises, self-paced recreational swimming, progressive/assisted weight-bearing exercise and activity.	Improve muscle strength, improve aerobic capacity, increase joint range of motion, improve confidence in weight-bearing, induce relaxation and promote enjoyment and variety of treatment.	3 (60 min)
Individual occupational therapy†	Relaxation techniques, postural re-education, cognitive—behavioural therapy (CBT) techniques, self-help coping strategies, pain management.	Induce relaxation, promote behavioural change, control pain and correct/improve poor posture.	3 (60 min)
Patient education	Coping with pain, benefits of exercise, joint protection, anatomy and pathology of hip pain, nutrition.	Activity modification, reduction of pain, promotes behavioural change, weight management, improve knowledge of treatment options, improve ability to relax and improve knowledge of self-help techniques.	2 (60 min)

Invited review

Finally, potential interventions for secondary and tertiary preventions in the Armed Forces could include physical rehabilitation programmes that comprised neuromuscular training, strength and conditioning supported with controlled return to work and appropriate medical grading, optimisation of nutritional status or possible orthoses.^{4 11 32} The MILO research programme also included a large, clinical randomised controlled trial (RCT) aiming to improve the management of intra-articular hip pain by modifying adverse hip joint forces through hip muscle strengthening, restoration of function and activity modification in UK military personnel with hip pain to demonstrate the effect of this in Service Personnel. These interventions are summarised in table 4. The results of both the MILO programme case–control study and RCT are due in 2023.

CONCLUSION

The understanding of OA has undergone a revolution in the past two decades. Service Personnel are at increased risk of this disabling condition and its sequelae, and there is a corresponding clinical and research focus within the DMS with the ADVANCE, BioMilOA and MILO studies. Understanding the specific molecular mechanisms underlying the high prevalence of OA in the military will enable the development of strategies to reduce the burden of OA among those serving. Moreover, the use of biomarkers, both following injury and longitudinally, offers the opportunity to risk stratify and phenotype both injured and non-injured individuals to optimise preventative strategies. The current priority for clinical care is early identification, with the correct and timely use of supportive measures, focused on symptomatic, not structural, OA, offering the opportunity to prevent or slow progression and therefore minimise subsequent morbidity, loss of function and years lived with disability. It is hoped that this paper will raise awareness of the presence and impact of OA, the available management options and the future directions of DMS research.

Twitter J Stocks @JoStocks

Acknowledgements This research is associated with the ADVANCE study, thanks to all the research staff, participants and funders involved. Thank you to Versus Arthritis for their support with the ongoing MILO and BioMilOA research studies.

Contributors OOS conceived the manuscript and prepared the first draft. FPB, RJC, JS, SK, AMV and ANB all provided expert input and critical review on subsequent drafts. All authors approved the final version. OOS acts as the guarantor.

Funding This work was supported by a grant from Versus Arthritis (21076) and funding from the UK Ministry of Defence (2122.030).

Competing interests None declared.

Patient consent for publication Not applicable.

Provenance and peer review Commissioned; externally peer reviewed.

ORCID iDs

- Oliver O'Sullivan http://orcid.org/0000-0002-9184-4713
- F P Behan http://orcid.org/0000-0001-9578-5725
- J Stocks http://orcid.org/0000-0002-7800-6002

REFERENCES

- O'Sullivan O, Ladlow P, Coppack RJ, et al. The BMJ Military Health military rehabilitation special issue . BMJ Mil Health 2022;168:253–5.
- 2 Strategic Command. Avoiding the Walker dip: A strategic delivery plan for DMS research 2021-2026; 2021.
- 3 Amoroso PJ, Canham ML. Chapter 4. Disabilities related to the musculoskeletal system: physical evaluation board data. *Mil Med* 1999;164(8 Suppl):1–73.
- 4 Rivera JC, Wenke JC, Buckwalter JA, et al. Posttraumatic osteoarthritis caused by battlefield injuries: the primary source of disability in warriors J am Acad Orthop Surg. J Am Acad Orthop Surg 2012;20:S64–9.
- 5 Mobasheri A, Batt M. An update on the pathophysiology of osteoarthritis. *Ann Phys Rehabil Med* 2016;59:333–9.

- 6 National Institute for health and care excellence. osteoarthritis in over 16S: diagnosis and management [NICE guideline [NG226]]. 2022. Available: https://www.nice.org. uk/guidance/ng226/chapter/Recommendations
- 7 Roos EM, Arden NK. Strategies for the prevention of knee osteoarthritis. Nat Rev Rheumatol 2016;12:92–101.
- 8 Lundin CR, Houe T, Sevelsted A, *et al.* Prolonged mounted patrolling is a risk factor for developing knee pain in Danish military personnel deployed to the Helmand province. *J R Army Med Corps* 2016;162:348–51.
- 9 Yavnai N, Bar-Sela S, Pantanowitz M, et al. Incidence of injuries and factors related to injuries in combat soldiers. BMJ Mil Health 2021;167:418–23.
- 10 Golightly YM, Shiue KY, Nocera M, *et al.* Association of traumatic knee injury with radiological evidence of knee osteoarthritis in military officers. *Arthritis Care & Research* 2023.
- 11 Whittaker JL, Culvenor AG, Juhl CB, et al. OPTIKNEE 2022: Consensus recommendations to optimise knee health after traumatic knee injury to prevent osteoarthritis. Br J Sports Med 2022;56:1393–405.
- 12 Whittaker JL, Losciale JM, Juhl CB, et al. Risk factors for knee osteoarthritis after traumatic knee injury: a systematic review and meta-analysis of randomised controlled trials and cohort studies for the OPTIKNEE. Br J Sports Med 2022;56:1406–21.
- 13 Vincent TL. Mechanoflammation in osteoarthritis pathogenesis. Semin Arthritis Rheum 2019;49:S36–8.
- 14 Buckwalter JA, Brown TD. Joint injury, repair and remodeling: roles in post-traumatic osteoarthritis. *Clin Orthop Relat Res* 2004;423:7–16.
- 15 Wasser JG, Hendershot BD, Acasio JC, *et al*. A comprehensive, multidisciplinary assessment for knee osteoarthritis following traumatic unilateral lower limb loss in service members. *Mil Med* 2022.
- 16 Garriga C, Goff M, Paterson E, et al. Clinical and molecular associations with outcomes at 2 years acute knee injury: a longitudinal study in the knee injury cohort at the Kennedy (KICK). Lancet Rheumatol 2021;3:e648–58.
- 17 Atkinson HF, Birmingham TB, Primeau CA, et al. Association between changes in knee load and effusion-synovitis: Evidence of mechano-inflammation in knee osteoarthritis using high tibial osteotomy as a model. Osteoarthritis and Cartilage 2021;29:222–9.
- 18 Jansen MP, Mastbergen SC. Joint distraction for osteoarthritis: clinical evidence and molecular mechanisms. Nat Rev Rheumatol 2022;18:35–46.
- 19 Szychlinska MA, Leonardi R, Al-Qahtani M, et al. Altered joint tribology in osteoarthritis: reduced lubricin synthesis due to the inflammatory process. New horizons for therapeutic approaches. Ann Phys Rehabil Med 2016;59:149–56.
- 20 Abdelrazig S, Ortori CA, Doherty M, et al. Metabolic signatures of osteoarthritis in urine using liquid chromatography-high resolution tandem mass spectrometry. *Metabolomics* 2021;17:29.
- 21 Villalvilla A, Larrañaga-Vera A, Lamuedra A, et al. Modulation of the inflammatory process by hypercholesterolemia in osteoarthritis. Front Med (Lausanne) 2020;7:566250.
- 22 Ding Z, Henson DP, Sivapuratharasu B, *et al*. The effect of muscle atrophy in people with unilateral transtibial amputation for three activities: gait alone does not tell the whole story. *J Biomech* 2023;149:111484.
- 23 Kim H, Seo J, Lee Y, et al. The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities. *Ther Adv Musculoskelet Dis* 2022;14.
- 24 Cooper C, Adachi JD, Bardin T, et al. How to define responders in osteoarthritis. Curr Med Res Opin 2013;29:719–29.
- 25 Watt FE, Corp N, Kingsbury SR, et al. Towards prevention of post-traumatic osteoarthritis: report from an international expert working group on considerations for the design and conduct of Interventional studies following acute knee injury. Osteoarthritis Cartilage 2019;27:23–33.
- 26 Kluzek S, Bay-Jensen A-C, Judge A, et al. Serum cartilage oligomeric matrix protein and development of radiographic and painful knee osteoarthritis. A community-based cohort of middle-aged women. *Biomarkers* 2015;20:557–64.
- 27 Juras V, Chang G, Regatte RR. Current status of functional MRI of osteoarthritis for diagnosis and prognosis. *Curr Opin Rheumatol* 2020;32:102–9.
- 28 Zhu L, Kamalathevan P, Koneva LA, et al. Variants in ALDH1A2 reveal an antiinflammatory role for retinoic acid and a new class of disease-modifying drugs in osteoarthritis. Sci Transl Med 2022;14.
- 29 Bennett AN, Dyball DM, Boos CJ, et al. Study protocol for a prospective, longitudinal cohort study investigating the medical and psychosocial outcomes of UK combat casualties from the Afghanistan war: the ADVANCE study. BMJ Open 2020;10:e037850.
- 30 Orr RM, Pope R, Johnston V, *et al*. Soldier occupational load carriage: a narrative review of associated injuries. *Int J Inj Contr Saf Promot* 2014;21:388–96.
- 31 Andersen KA, Grimshaw PN, Kelso RM, et al. Musculoskeletal lower limb injury risk in army populations. Sports Med Open 2016;2:22.
- 32 Coppack RJ, Bilzon JL, Wills AK, et al. Physical and functional outcomes following multidisciplinary residential rehabilitation for prearthritic hip pain among young active UK military personnel. BMJ Open Sport Exerc Med 2016;2:e000107.